Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Novo Holdings

Industrifonden

Boehringer Ingelheim Venture Fund

LU Holding

Asgard Therapeutics

Asgard Therapeutics is a Swedish private biotech company that explores direct cell reprogramming technologies to develop cancer immunotherapies. The company's lead program, AT-108, is designed to initiate immune responses mediated by professional antigen presenting cells, overcoming logistical and manufacturing hurdles of conventional cell-based therapies.

COM:ASGARDTHX

Asgard Therapeutics

Filings Not Available